arrow
L

L. Bosquet

unicancer
H指数:13
被引数:731

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort

与转移性乳腺癌一线抗HER2为基础治疗中表现出非凡疗效相关的临床特征:来自ESME国家队列的真实世界数据

Breast
IF7.9
2026-10-130
OA
Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database

人表皮生长因子受体2低表达、激素受体阳性转移性乳腺癌的化疗结局:来自法国多中心ESME数据库的见解

Breast
IF7.9
2026-09-270
OA
Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

广泛期小细胞肺癌中,先前接受免疫治疗不影响二线化疗的疗效:来自法国ESME全国真实世界队列的研究结果

2026-08-070
OA
Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France

法国晚期和转移性肺癌的治疗模式与结果:来自法国流行病学策略与医学经济学(ESME)数据库的研究结果

2026-08-010
PRE
Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women

老年转移性三阴性乳腺癌患者的特征、治疗及生存情况:基于ESME mBC真实世界全国队列研究,并与年轻女性进行比较

2026-05-220
OAAI
Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database

高级别浆液性卵巢癌接受高强度细胞减灭术和化疗:淋巴结受累的预后影响:法国国家ESME-Unicancer数据库分析

2026-03-250
PRE
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort

老年与年轻HR阳性HER2阴性转移性乳腺癌女性患者真实世界多中心法国ESME队列中的近期治疗与生存趋势

2025-12-050
PRE
Surgical Approach and Maintenance Therapy in Advanced Low-Grade Serous Ovarian Cancer: Insights from the French ESME Database

晚期低级别浆液性卵巢癌的手术治疗与维持治疗:来自法国ESME数据库的见解

2025-11-140
PRE
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

CDK4/6抑制剂治疗后疾病进展的HR阳性/HER2阴性转移性乳腺癌患者中真实世界的治疗模式与疗效:ESME-MBC队列研究

2025-09-170
PREAI
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database

无铂间期(PFI)及维持治疗在复发性卵巢癌中的作用:解释生存率的法国真实世界ESME卵巢数据库分析

2025-08-070
PRE
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network

PARP抑制剂在铂敏感复发性卵巢癌中的维持治疗:来自Unicancer网络的现实世界经验

2025-05-110
OA
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

真实世界中,携带表皮生长因子受体外显子20插入突变的晚期非小细胞肺癌患者的前线治疗方案,以及PAPILLON研究中与阿曼曲单抗联合化疗的调整后比较。

2025-05-010
PRE
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
2025-02-200
OAAI
Advanced High-Grade Serous Ovarian Cancer Treated With Intensive Cytoreductive Surgery And Chemotherapy: Prognostic Impact Of Lymph Node Involvement: Analysis Of The French National ESME-Unicancer Database

高级别浆液性卵巢癌经强化细胞减灭术和化疗治疗:淋巴结受累的预后影响:法国国家ESME-Unicancer数据库分析

2025-02-010
PRE
A Retrospective Multicentre Study To Evaluate The Impact Of Platinum-Free Interval On Progression-Free And Overall Survival In Patients With Recurrent Epithelial Ovarian Cancer, Using Real-World Data From The ESME Database

一项回顾性多中心研究,旨在评估无铂间隔对复发性上皮性卵巢癌患者无进展生存期和总生存期的影响,使用来自ESME数据库的真实世界数据。

2025-02-010
PRE
Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database

卡培他滨(CAPE)是否是内分泌治疗(ET)进展后雌激素受体阳性(ER+)人表皮生长因子受体2阴性(HER2-)转移性乳腺癌(MBC)的最佳治疗(trt)选择:一项基于ESME真实世界数据库的分析

2024-09-010
PRE
Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME database

法国多中心ESME数据库中卵巢透明细胞癌(OCCC)的初始管理和长期预后

2024-09-010
PRE
Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database
2024-09-010
PRE